eMedicine Specialties > Radiology > Gastrointestinal
Portal Vein Thrombosis: Imaging
Updated: Oct 1, 2009
Radiography
Findings
Plain radiographs may reveal hepatosplenomegaly, an enlarged azygos vein, and paraspinal varices. Esophageal varices that consist of dilated submucosal veins in the lower esophagus occur chiefly as a consequence of portal hypertension, mostly in cirrhosis. The varices appear as beaded or serpiginous translucent filling defects. Large esophageal varices are obvious and appear as nodular or vermiform, changeable filling defects within the esophagus. Smaller varices appear as scalloped esophageal folds, which are better seen on recumbent radiographs, because they tend to disappear on upright images.
Computed Tomography
Findings
Portal vein thrombosis. Portal venous–phase enhanced axial CT scan, obtained in the same patient as in Images 1-3 in Multimedia, shows no flow in the portal vein. Note the multiple low-attenuating masses at the periphery of the right lobe of the liver.
Portal vein thrombosis. Portal venous–phase enhanced axial CT scan, obtained in the same patient as in Images 1-4 in Multimedia, shows a low-attenuating mass in the termination of the splenic vein (arrow). Note the multiple low-attenuating masses at the periphery of the right lobe of the liver.
Portal vein thrombosis. Portal venous–phase enhanced axial CT scan, obtained in the same patient as in Images 1-5 in Multimedia, shows an enlarged left gastric vein associated with a low-attenuating mass in the vein. No contrast enhancement is seen in the vein; this finding is suggestive of thrombosis (arrow).
Contrast-enhanced axial CT depicts cavernous transformation following portal venous thrombosis. The portal venous thrombus is extending from the superior mesenteric vein (right image-arrow). Note the small ascites.
Coronal reconstruction of contrast-enhanced CT depicts cavernous transformation following portal venous thrombosis. Note the gallbladder varices (red arrow) and a dilated bile duct (white arrow). The appearances suggest portal biliopathy.
Axial contrast-enhanced CT images of the liver depicting dilated ducts (white arrow) and portal vein thrombus (red arrow) Note the varices around the spleen (same patient as in Images 14-19 in Multimedia).
The portal vein supplies 75% of the blood flow to the liver. Therefore, peak liver contrast enhancement occurs during the portal venous phase, about 60 seconds after the start of a bolus injection of contrast material.25 With helical CT, a liver examination requires about 20 seconds to complete; images can usually be acquired in one breath hold.26
This technique can be extended to acquire a dual-phase contrast-enhanced CT scan in which the liver is imaged twice with a single contrast agent bolus, first during the arterial phase and then through portal venous phase. Dual-phase CT is indicated in some cases involving benign or malignant lesions in which vascular characteristics suggest the correct diagnosis (see Images above and Images 4-6, 13, 14, 16-17 in Multimedia).
Angiographically assisted CT, or CT arterial portography, can provide better delineation of the portal venous system and portal venous enhancement of the liver. An angiographic catheter is placed in the common celiac axis, hepatic artery, or superior mesenteric artery by using a modified Seldinger technique via the femoral artery. Image acquisition begins 3-5 seconds after injection of the contrast agent is initiated. The examination should be completed as soon as possible, before the contrast material recirculates. To prevent significant artifacts related to the density of the contrast material, 70 mL of dilute (1-30%) iodinated contrast agent is used with an infusion rate of 2 mL/s. Although angiographically assisted CT can produce elegant images, it is invasive, expensive, and not widely accepted.
On contrast-enhanced CT scans, PVT may be depicted as a low-attenuating center in the portal vein surrounded by peripheral enhancement. Portal vein attenuation is 20-30 HU less than that of the aorta.
CT angiography (CTA) is an application of helical CT. The rapidity of helical CT allows the maintenance of a higher concentration of intravenous contrast medium, particularly through the arterial enhancement phase, and it has the capability of 3-dimensional (3D) reconstruction. Both peripheral intravenous injections of contrast agent and CT arterial portography have been used as with CTA. CTA has shown great promise in the evaluation of hepatic vessels before liver resection. It provides preoperative surgical information about the segmental location of liver tumors, the segmental venous anatomy, and the presence of significant arterial anomalies. The value of CTA in the evaluation of portal hypertension is unclear, but CTA is likely to be useful because it may delineate the collateral vessels, varices, and other findings in patients with portal hypertension.
Magnetic Resonance Imaging
Findings
MRCP showing intrahepatic dilatation of the right lobe bile ducts and a long stricture of the common bile duct (same patient as in Images 14-19 in Multimedia).
T1-contrast-enhanced coronal MR images showing thrombus within the main portal vein and a cavernous transformation of portal vein at the porta hepatis (same patient as in Images 14-19 in Multimedia).
The vascular anatomy of the liver may be outlined by using spin-echo and gradient-recalled-echo (GRE) techniques, but these techniques cannot demonstrate the direction of portal flow. Time-of-flight MRI with bolus tracking has been successful in the assessment of portal hypertension and its sequelae. Phase-contrast sequences can also be used to evaluate the portal vein, and phase-contrast cine MRA can show the direction of portal venous flow and the presence of portal vein thrombus. Magnetic resonance evaluation of the portal venous system accurately demonstrates thrombosis and the collateral circulation. Gadolinium enhancement is useful in this application (see Image above and Image 18 in Multimedia).27,28,29
Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have recently been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Fibrosing Dermopathy. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans.
As of late December 2006, the FDA had received reports of 90 such cases of NSF/NFD. Worldwide, over 200 cases have been reported, according to the FDA. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see the FDA Public Health Advisory or Medscape.
Degree of Confidence
MRCP coupled with dynamic 3D gradient-echo imaging can not only detect portal vein occlusion, cavernous transformation, and gallbladder varices but also depict bile duct abnormalities associated with portal biliopathy.30,31,32
False Positives/Negatives
Lin and associates compared surgery and X-ray portography with 3D CE MRA in patients with portal vein involvement from hepatocellular carcinoma.33 The overall sensitivity with 3D CE MRA was 99%; the specificity was 96%; the positive predictive value was 91%; and the negative predictive value was 99%. The accuracy in diagnosis of the main portal vein was 100%. 3D CE MRA resulted in 7 false-positive interpretations involving 6 left portal veins and 1 right portal vein. One false-negative diagnosis was made with right portal vein involvement.
Shah and associates compared MRI with intraoperative findings in the diagnosis of portal vein thrombosis in transplantation candidates. In this study, the sensitivity and specificity of MRI for detecting main PVT were 100% and 98%, respectively. The cause of discordance between findings on MRI and at transplantation in 2 cases was a diminutive caliber of the main portal vein that was interpreted as recanalized chronic thrombosis on MRI. The major reason for a false-positive MRI is a diminutive but patent portal vein.29
An extremely slow portal venous flow is considered to be the cause of false-positive findings with unenhanced MRI and sonography.34
Ultrasonography
Findings
Portal vein thrombosis. Longitudinal oblique sonogram was obtained through the liver in a 36-year-old woman with a known history of Leber optic atrophy (hereditary optic neuroretinopathy) and alcohol abuse who presented with nonspecific complaints of ill health and vague abdominal pain. Image shows ascites and a bright liver (fatty). The portal vein has a linear echogenic structure running the length of the portal vein (solid arrow). A complex cystic mass is present within the liver (open arrow).
Portal vein thrombosis. Power Doppler sonogram of the liver, obtained in the same patient as in Image 1 in Multimedia, shows blood flow around an intraluminal filling defect in the portal vein (P).
Portal vein thrombosis. Longitudinal oblique sonogram was obtained in a 28-year-old woman who was referred for gallbladder ultrasonography. On questioning, she gave a history of an episode of severe pyrexial illness and dehydration during childhood. The image shows several vascular tubular structures at the porta hepatis, which are suggestive of a cavernous transformation.
Portal vein thrombosis. Color Doppler sonogram, obtained in the same patient as in Image 8 in Multimedia, shows flow in the cavernous transformation.
Color Doppler ultrasonography depicts a vascularized HCC portal venous thrombus.
Ultrasound reveals an echogenic partially recanalized portal vein thrombus. The patient was a 36-year-old woman with idiopathic chronic portal vein thrombosis of 2 years' duration. She presented with cholestatic jaundice (same patient as in Images 14-19 in Multimedia).
PVT is being recognized with increasing frequency at ultrasonography. Abdominal sepsis and reduced portal blood flow resulting from hepatic parenchymal disease are the major causes. Transient PVT is also being recognized with increasing frequency, partly because of the great increase in the use of ultrasonography in the evaluation of patients with abdominal inflammation, such as appendicitis. Tumor in the portal vein may have an appearance identical to that of thrombosis,35 but this appearance is far less common than others (see Images above and Images 1-3, 8-12, 15 in Multimedia).
On sonograms, echogenic lesions may be present in the portal vein. Clot with variable echogenicity may be depicted. The clot usually has moderate echogenicity, but if it is recently formed, it may be hypoechoic. Patent vessels may have increased intraluminal echogenicity because of erythrocyte rouleaux formation, which makes slow-flowing blood slightly echogenic. Increased or decreased echogenicity may be observed in the lumen of the portal vein. In isolation, this finding is not sufficient to diagnose or exclude PVT.
PVT eliminates the usual venous flow signal from the lumen of the portal vein during either pulsed or color flow Doppler imaging. Color flow Doppler images can show flow around a thrombus that partially blocks the vein. However, if flow is sluggish, the Doppler signal may not be detected. Color flow may be present in other small collateral vessels.36
Incomplete occlusion may occur. This is common with neoplastic invasion. Alternatively, thrombolytic recanalization may occur. The 2 cannot be differentiated on sonograms. Cavernous malformation, spontaneous shunts, and splenorenal and portosystemic collaterals may be seen. The underlying cause (eg, hepatocellular carcinoma, metastases, cirrhosis, pancreatic neoplasms) may be evident. The incidence of PVT is reported to be low in portal hypertension.
The string sign—that is, thickening of the portal vein with narrowing of its lumen—is assumed to be caused by portal phlebitis. This is considered a precursor of PVT in patients with acute pancreatitis. The portal vein thrombus may be calcified. The diameter of the portal vein is larger than 15 mm in 38% of the cases of PVT.37
Angiography
Findings
Among catheter-directed techniques, arterial portography is now the preferred method for evaluating the portal venous system because it is less invasive and has a lower complication rate than the other methods (eg, splenoportography). The method involves the indirect opacification of the portal venous system with an injection of contrast material into the splenic vein to outline the splenic and portal veins or superior artery to outline the superior mesenteric and portal veins.
The 3 major indications for arterial portography are the following: (1) to examine patients with portal hypertension and its sequelae, particularly when surgical treatment is planned; (2) to determine the resectability of hepatic and pancreatic tumors when both the arterial- and venous-phase angiographic findings make a significant contribution; and (3) to perform transcatheter embolization, in cases of metastases of islet cell tumors or carcinoid metastases, or chemoembolization, in cases of hepatocellular carcinoma. (A widely or partly patent portal vein is a prerequisite for such treatment.)38
Patient preparation and contraindications are the same as those of conventional angiography. Selective catheters are used to cannulate the appropriate vessel. In a superior mesenteric artery injection, the tip of the catheter is placed to enable opacification of all the branches with contrast material. Before the delivery of the contrast agent, a vasodilator (tolazoline [Priscoline], papaverine, or prostaglandin E) is administered to improve opacification of the portal vein.
Manual or digital subtraction is necessary. If digital subtraction is used, the administration of an anticholinergic drug (eg, glucagon) before imaging reduces bowel motion. Selective injection of the superior mesenteric artery can be used to outline the superior mesenteric and portal veins. For splenic and/or portal vein delineation, splenic artery catheterization is chosen. Injection of the left gastric artery consistently demonstrates esophageal varices.
For details about splenoportography, see Portal Hypertension.
Another technique for opacifying the portal system is wedged hepatic venous injections of carbon dioxide.39 The low viscosity of the gas allows it to readily float across the hepatic sinusoids, successfully opacifying the portal vein in most cases. See Carbon Dioxide Angiography for details and images.
Degree of Confidence
Diagnostic modalities such as ultrasonography, CT, and MRI have reduced the diagnostic importance of arteriography in the diagnosis of liver tumors. The role of liver angiography seems to be limited to the occasional mapping of the vascular anatomy before surgery (now largely performed with MRA or CTA) and the transcatheter treatment of liver tumors. Venous-phase imaging in the celiac axis and superior angiography provide sufficient detail to make direct portography unnecessary in most cases.
More on Portal Vein Thrombosis |
| Overview: Portal Vein Thrombosis |
 Imaging: Portal Vein Thrombosis |
| Follow-up: Portal Vein Thrombosis |
| Multimedia: Portal Vein Thrombosis |
| References |
| Further Reading |
| « Previous Page | Next Page » |
References
Patel N, Haskal ZJ, Kerlan RK. Portal Hypertension: Diagnosis and Interventions. 2nd ed. Society of Cardiovascular and Interventional Radiology;. 2001.
Radovich PA. Portal vein thrombosis and liver disease. J Vasc Nurs. Mar 2000;18(1):1-5. [Medline].
Sheen CL, Lamparelli H, Milne A. Clinical features, diagnosis and outcome of acute portal vein thrombosis. QJM. Aug 2000;93(8):531-4. [Medline].
Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis. J Clin Gastroenterol. Sep 1 2009;[Medline].
Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, et al. Efficacy of a Hepatectomy and a Tumor Thrombectomy for Hepatocellular Carcinoma with Tumor Thrombus Extending to the Main Portal Vein. J Gastrointest Surg. Sep 2 2009;[Medline].
Giorgio A, Di Sarno A, de Stefano G, Farella N, Scognamiglio U, de Stefano M, et al. Hepatocellular carcinoma with cirrhosis: are patients with neoplastic main portal vein invasion eligible for percutaneous radiofrequency ablation of both the nodule and the portal venous tumor thrombus?. AJR Am J Roentgenol. Oct 2009;193(4):948-54. [Medline].
Song ZZ, Huang M, Jiang TA, Zhao QY, Yao L, Mou Y, et al. Diagnosis of portal vein thrombosis discontinued with liver tumors in patients with liver cirrhosis and tumors by contrast-enhanced US: A pilot study. Eur J Radiol. May 21 2009;[Medline].
Danno K, Ikeda M, Sekimoto M, Sugimoto T, Takemasa I, Yamamoto H, et al. Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Surgery. May 2009;145(5):457-64; discussion 465-6. [Medline].
Shirai S, Sato M, Suwa K, Kishi K, Shimono C, Sonomura T, et al. Feasibility and Efficacy of Single Photon Emission Computed Tomography-Based Three-Dimensional Conformal Radiotherapy for Hepatocellular Carcinoma 8 cm or more with Portal Vein Tumor Thrombus in Combination with Transcatheter Arterial Chemoembolization. Int J Radiat Oncol Biol Phys. Jun 17 2009;[Medline].
Shirai S, Sato M, Suwa K, Kishi K, Shimono C, Kawai N, et al. Single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus. Int J Radiat Oncol Biol Phys. Mar 1 2009;73(3):824-31. [Medline].
Ricci P, Cantisani V, Biancari F. Contrast-enhanced color Doppler US in malignant portal vein thrombosis. Acta Radiol. Sep 2000;41(5):470-3. [Medline].
Vleggaar FP, Van Buuren HR, Laméris JS. [Bile duct lesions in portal vein thrombosis]. Ned Tijdschr Geneeskd. Oct 9 1999;143(41):2057-62. [Medline].
Maalouf M, Papasavas P, Goitein D, Caushaj PF, Gagne D. Portal vein thrombosis after laparoscopic splenectomy for systemic mastocytosis: a case report and review of the literature. Surg Laparosc Endosc Percutan Tech. Apr 2008;18(2):219-21. [Medline].
Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis. Thromb Haemost. Apr 2008;99(4):675-82. [Medline].
Sakha SH, Rafeey M, Tarzamani MK. Portal venous thrombosis after umbilical vein catheterization. Indian J Gastroenterol. Nov-Dec 2007;26(6):283-4. [Medline].
Rubabaza P, Persadie RJ. Two Cases of Umbilical Vein Thrombosis, One With Associated Portal Vein Thrombosis. J Obstet Gynaecol Can. Apr 2008;30(4):338-343. [Medline].
de Suray N, Pranger D, Brenard R. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases. Acta Gastroenterol Belg. Jan-Mar 2008;71(1):39-41. [Medline].
El-Matary W, Roberts EA, Kim P, Temple M, Cutz E, Ling SC. Portal hypertensive biliopathy: a rare cause of childhood cholestasis. Eur J Pediatr. Feb 13 2008;[Medline].
Perego P, Cozzi G, Bertolini A. Portal biliopathy. Surg Endosc. Feb 2003;17(2):351-2. [Medline].
Chandra R, Kapoor D, Tharakan A, Chaudhary A, Sarin SK. Portal biliopathy. J Gastroenterol Hepatol. Oct 2001;16(10):1086-92. [Medline].
Colle I, Van Vlierberghe H, Pattyn P, Troisi R, Vogelaers D, de Hemptinne B, et al. Cholestasis as presenting symptom of portal cavernoma. Hepatol Res. Jan 2003;25(1):32-37. [Medline].
von Herbay A, Frieling T, Haussinger D. Color Doppler sonographic evaluation of spontaneous portosystemic shunts and inversion of portal venous flow in patients with cirrhosis. J Clin Ultrasound. Sep 2000;28(7):332-9. [Medline].
Stein M, Link DP. Symptomatic spleno-mesenteric-portal venous thrombosis: recanalization and reconstruction with endovascular stents. J Vasc Interv Radiol. Mar 1999;10(3):363-71. [Medline].
Parvey HR, Raval B, Sandler CM. Portal vein thrombosis: imaging findings. AJR Am J Roentgenol. Jan 1994;162(1):77-81. [Medline].
Acosta S, Alhadad A, Ekberg O. Findings in multi-detector row CT with portal phase enhancement in patients with mesenteric venous thrombosis. Emerg Radiol. Mar 18 2009;[Medline].
Novick SL, Fishman EK. Portal vein thrombosis: spectrum of helical CT and CT angiographic findings. Abdom Imaging. Sep-Oct 1998;23(5):505-10. [Medline].
Glockner JF, Forauer AR, Solomon H. Three-dimensional gadolinium-enhanced MR angiography of vascular complications after liver transplantation. AJR Am J Roentgenol. May 2000;174(5):1447-53. [Medline].
Matsuo M, Kanematsu M, Nishigaki Y, Kondo H, Goshima S, Maeda S, et al. Pseudothrombosis with T2-weighted fast spin-echo MR images caused by static portal venous flow in severe cirrhosis. J Magn Reson Imaging. Feb 2002;15(2):199-202. [Medline].
Shah TU, Semelka RC, Voultsinos V, Elias J Jr, Altun E, Pamuklar E, et al. Accuracy of magnetic resonance imaging for preoperative detection of portal vein thrombosis in liver transplant candidates. Liver Transpl. Nov 2006;12(11):1682-8. [Medline].
Chaudhary A, Dhar P, Sarin SK, Sachdev A, Agarwal AK, Vij JC, et al. Bile duct obstruction due to portal biliopathy in extrahepatic portal hypertension: surgical management. Br J Surg. Mar 1998;85(3):326-9. [Medline].
Chevallier P, Denys A, Novellas S, Schmidt S, Schnyder P, Bruneton JN. Magnetic resonance cholangiography features of biliary abnormalities due to cavernous transformation of the portal vein. Clin Imaging. May-Jun 2006;30(3):190-4. [Medline].
Shin SM, Kim S, Lee JW, Kim CW, Lee TH, Lee SH, et al. Biliary abnormalities associated with portal biliopathy: evaluation on MR cholangiography. AJR Am J Roentgenol. Apr 2007;188(4):W341-7. [Medline].
Lin J, Zhou KR, Wang JH, Yan ZP. [Portal vein involvement by hepatocellular carcinoma: diagnosis with three-dimensional contrast-enhanced MR angiography.]. Zhonghua Yi Xue Za Zhi. Feb 2 2005;85(5):308-12. [Medline].
Matsuo M, Kanematsu M, Hoshi H. Portal vein thrombosis mimicking hypovascular hepatic neoplasm: dynamic MR imaging findings. AJR Am J Roentgenol. Oct 1999;173(4):1060-2. [Medline].
Sorrentino P, D'Angelo S, Tarantino L, Ferbo U, Bracigliano A, Vecchione R. Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. World J Gastroenterol. May 14 2009;15(18):2245-51. [Medline].
Chen Y, Chen J, Luo B. [Colored Doppler ultrasound-guided fine-needle aspiration biopsy of portal vein thrombosis: value in diagnosis and assessment of therapeutic efficacy for portal vein thrombosis]. Zhonghua Zhong Liu Za Zhi. Sep 1997;19(5):362-4. [Medline].
Zwiebel WJ. Sonographic diagnosis of hepatic vascular disorders. Semin Ultrasound CT MR. Feb 1995;16(1):34-48. [Medline].
Meyer BC, Witschel M, Frericks BB, Voges M, Hopfenmüller W, Wolf KJ, et al. The value of combined soft-tissue and vessel visualisation before transarterial chemoembolisation of the liver using C-arm computed tomography. Eur Radiol. Sep 2009;19(9):2302-9. [Medline].
Martinez-Cuesta A, Elduayen B, Vivas I. CO(2) wedged hepatic venography: technical considerations and comparison with direct and indirect portography with iodinated contrast. Abdom Imaging. Nov-Dec 2000;25(6):576-82. [Medline].
Vogl T, Hidajat N, Schroder RJ. [Recanalization of an extensive fresh portal vein thrombosis by transjugular intrahepatic portosystemic stent-shunt (TIPS)]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. Aug 1999;171(2):163-5. [Medline].
Yamashita K, Tsukuda H, Mizukami Y. Hepatic infarction with portal thrombosis. J Gastroenterol. Oct 1997;32(5):684-8. [Medline].
Luo Y, Fan YT, Lu Q, Li B, Wen TF, Zhang ZW. CEUS: a new imaging approach for postoperative vascular complications after right-lobe LDLT. World J Gastroenterol. Aug 7 2009;15(29):3670-5. [Medline].
Clevert DA, Stickel M, Minaifar N, Löhe F, Graeb C, Jauch KW, et al. Contrast-enhanced ultrasound in liver transplant: first results and potential for complications in the postoperative period. Clin Hemorheol Microcirc. 2009;43(1):83-94. [Medline].
Condat B, Pessione F, Hillaire S. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. Feb 2001;120(2):490-7. [Medline].
Sehgal M, Haskal ZJ. Use of transjugular intrahepatic portosystemic shunts during lytic therapy of extensive portal splenic and mesenteric venous thrombosis: long-term follow-up. J Vasc Interv Radiol. Jan 2000;11(1):61-5. [Medline].
Bilbao JI, Vivas I, Elduayen B. Limitations of percutaneous techniques in the treatment of portal vein thrombosis. Cardiovasc Intervent Radiol. Sep-Oct 1999;22(5):417-22. [Medline].
Walser EM, NcNees SW, DeLa Pena O. Portal venous thrombosis: percutaneous therapy and outcome. J Vasc Interv Radiol. Jan-Feb 1998;9(1 Pt 1):119-27. [Medline].
Further Reading
Related eMedicine topics
Liver Transplantation, Complications
Mesenteric Venous Thrombosis
Portal Vein Obstruction
Portal Hypertension
Keywords
PVT, portal venous thrombosis, transient portal vein thrombosis, cavernous transformation of the portal vein, splenic vein thrombosis, angina, pseudocholangiocarcinoma, pancreatitis, thrombophlebitis, transjugular intrahepatic portosystemic shunt, TIPS
